Decitabine plus chemotherapy before stem cell transplant for high-risk leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether adding decitabine plus chemotherapy before a stem cell transplant can better control “minimal residual disease” (very small amounts of leukemia left behind) in certain high-risk acute leukemia types. It may help reduce the chance of the leukemia coming back after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute leukemia with one of these specific genetic types: MLL-r, TLS-ERG, or SIL-TAL1
- Before your planned stem cell transplant, tests show minimal residual disease (tiny remaining leukemia)
- You are not pregnant
- You do not currently have a severe infection that is not under control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two drugs (ruxolitinib and decitabine) to the standard chemotherapy before a stem cell transplant can help prevent leukemia from coming back. It is for people with acute myeloid leukemia who have a suitable donor and are otherwise healthy enough for transplant.
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your leukemia or MDS from coming back. It is for people whose disease is at high risk for relapse.
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
This trial tests two cancer medicines—decitabine or azacitidine (also called “hypomethylating agents”) plus venetoclax—given after an allogeneic stem cell transplant to help prevent relapse in people with high-risk AML or MDS. If you have measurable remaining leukemia cells after transplant, this study may be especially relevant.
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
This trial tests whether a new drug combination (Dec-FB4) works better than an existing one (FB4) as preparation for a stem cell transplant in people with acute myeloid leukemia that is in remission. The goal is to improve outcomes for patients who have a suitable donor.
Hear when a new Stem Cell Transplant Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.